Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
HZNP was delisted on the 5th of October, 2023.
198 hedge funds and large institutions have $2.31B invested in Horizon Therapeutics Public Limited Company Ordinary Shares in 2016 Q2 according to their latest regulatory filings, with 50 funds opening new positions, 76 increasing their positions, 51 reducing their positions, and 45 closing their positions.
181% more call options, than puts
Call options by funds: $78.5M | Put options by funds: $27.9M
49% more repeat investments, than reductions
Existing positions increased: 76 | Existing positions reduced: 51
11% more first-time investments, than exits
New positions opened: 50 | Existing positions closed: 45
1% more funds holding
Funds holding: 196 → 198 (+2)
0% more capital invested
Capital invested by funds: $2.31B → $2.31B (+$3.85M)
0% more funds holding in top 10
Funds holding in top 10: 7 → 7 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$60.5M |
| 2 |
DCM
Discovery Capital Management
South Norwalk,
Connecticut
|
+$56.7M |
| 3 |
KCM
Kingdon Capital Management
New York
|
+$46.6M |
| 4 |
State Street
Boston,
Massachusetts
|
+$40.7M |
| 5 |
Fiera Capital (Canada)
Montreal,
Quebec, Canada
|
+$28.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LPC
Lone Pine Capital
Greenwich,
Connecticut
|
-$232M |
| 2 |
VAM
Visium Asset Management
New York
|
-$46.5M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$33.7M |
| 4 |
RIM
RS Investment Management
San Francisco,
California
|
-$24.1M |
| 5 |
GAM
Gotham Asset Management
New York
|
-$17.5M |
HZNP Hedge Fund Activity: Q2 2016 in Review
198 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) for Q2 2016, worth a combined $2.31B — up 0.17% from $2.31B a quarter earlier.
Buyers outnumbered sellers: 50 funds opened new HZNP positions and 45 closed out — a net gain of 5 holders — while 76 added to existing stakes and 51 trimmed.
The largest buyer was BlackRock Fund Advisors, adding an estimated $60.5M. The largest seller was Lone Pine Capital, exiting entirely with an estimated $232M sold.
- 198 institutional investors held Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) as of Q2 2016, up from 196 in Q1 2016.
- Funds reported $2.31B of Horizon Therapeutics Public Limited Company Ordinary Shares stock for Q2 2016, up 0.17% quarter-over-quarter.
- 50 funds opened new Horizon Therapeutics Public Limited Company Ordinary Shares positions in Q2 2016 and 45 closed out, a net change of +5 holders.
- The largest Horizon Therapeutics Public Limited Company Ordinary Shares buyer in Q2 2016 was BlackRock Fund Advisors, an estimated $60.5M added.
- The largest Horizon Therapeutics Public Limited Company Ordinary Shares seller in Q2 2016 was Lone Pine Capital, an estimated $232M sold.
Based on aggregated 13F filings for Q2 2016.